Safety Communication

Dear Healthcare Professional,

As part of Risk Management Plan (RMP) conducted by pharmaceutical industry, PT Roche Indonesia communicate safety information for doctor related to Esbriet (Pirfenidone).

Esbriet (Pirfenidone) is medicine for mild to moderate Idiopathic Pulmonary Fibrosis (IPF) in adult. This safety information contains important elements for Esbriet (Pirfenidone) use especially related to photosensitivity and hepatic function.

For more detail information can be found in the Safety Information for Doctor from PT Roche Indonesia.

 

Regards,

National Pharmacovigilance Center

National Agency of Drug and Food Control (NADFC)


Download : Informasi Keamanan Bagi Dokter Terkait Penggunaan ESBRIET (pirfenidone).pdf
Poll
How do you think the content and appearance of this website?




logo dsras Email Rapid Alert System

Selamat email anda telah berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia.

 

logo dsras Email Rapid Alert System

Anda ingin berhenti berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia?